Abstract
The development of an effective vaccine for tuberculosis and its progression towards clinical trials will require greater knowledge about the effector mechanisms of induction of immune response. Currently, there are several strategies under development for TB, but the lack of protective biomarkers has been a limiting factor. An enormous effort has been devoted to the study of the immunolo…